Published in BMC Cancer on January 31, 2006
Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist (2010) 1.94
Head and neck cancer: an evolving treatment paradigm. Cancer (2008) 1.21
Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol (2009) 1.16
Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 1.15
The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol (2006) 1.13
Dysphagia in head and neck cancer patients treated with chemoradiotherapy. Dysphagia (2009) 1.04
Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Qual Life Res (2013) 1.04
The diagnosis and treatment of oral cavity cancer. Dtsch Arztebl Int (2012) 1.00
Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience. Head Neck (2010) 0.98
Current concepts in clinical radiation oncology. Radiat Environ Biophys (2013) 0.97
Constitutive gene expression profile segregates toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy. Radiat Oncol (2009) 0.89
Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity. Strahlenther Onkol (2012) 0.89
Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience. Br J Radiol (2011) 0.89
Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment. Radiat Oncol (2012) 0.87
Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer. J Cancer Res Clin Oncol (2008) 0.87
Diffusion-weighted magnetic resonance imaging in neck lymph adenopathy. Cancer Imaging (2008) 0.85
The potential of helical tomotherapy in the treatment of head and neck cancer. Oncologist (2013) 0.84
Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol. BMC Cancer (2010) 0.84
Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors. Radiat Oncol (2012) 0.84
Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature. Rep Pract Oncol Radiother (2015) 0.83
Adherence to and uptake of clinical practice guidelines: lessons learned from a clinical practice guideline on chemotherapy concomitant with radiotherapy in head-and-neck cancer. Curr Oncol (2015) 0.82
Combined low initial DNA damage and high radiation-induced apoptosis confers clinical resistance to long-term toxicity in breast cancer patients treated with high-dose radiotherapy. Radiat Oncol (2011) 0.82
Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer. Tumour Biol (2014) 0.81
Analysis of the outcome of concurrent neoadjuvant chemoradiotherapy with S-1 compared to super-selective intra-arterial infusion for oral squamous cell carcinoma. Oncol Lett (2012) 0.80
The development and validation of a quality-of-life questionnaire for head and neck cancer patients with enteral feeding tubes: the QOL-EF. Support Care Cancer (2010) 0.79
Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer. J Radiat Res (2013) 0.78
Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells. BMC Genomics (2015) 0.78
Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma. Cancer Res Treat (2014) 0.78
Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas. Cancers (Basel) (2016) 0.77
Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments. Biomed Res Int (2013) 0.77
Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial. Radiat Oncol (2012) 0.76
Evaluation of swallowing function after supracricoid laryngectomy as a primary or salvage procedure. Dysphagia (2015) 0.76
Evaluation of neo-adjuvant, concurrent and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma: a meta-analysis. J Dent (Tehran) (2014) 0.76
Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells. Oncotarget (2016) 0.75
Highly proliferative neuroendocrine carcinoma - influence of radiotherapy fractionation on tumor response. Radiat Oncol (2008) 0.75
ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy. Oncotarget (2016) 0.75
Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer Therapy. PLoS One (2015) 0.75
Hazards and risks in oncology: radiation oncology. GMS Curr Top Otorhinolaryngol Head Neck Surg (2013) 0.75
Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol. Radiat Oncol (2017) 0.75
The Role of Lymphocytes in Radiotherapy-Induced Adverse Late Effects in the Lung. Front Immunol (2016) 0.75
Concurrent hyperfractionated chemoradiotherapy for head and neck squamous cell carcinoma: the prognostic impact of the overall treatment time and completion rates of chemotherapy. Springerplus (2015) 0.75
Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review. J Otolaryngol Head Neck Surg (2017) 0.75
The Management of Patients after Surgical Treatment of Maxillofacial Tumors. Biomed Res Int (2016) 0.75
The role of systemic treatment before, during, and after definitive treatment. Otolaryngol Clin North Am (2013) 0.75
Concurrent radiochemotherapy in advanced hypopharyngeal cancer. Radiat Oncol (2010) 0.75
Five-year follow-up of concomitant accelerated hypofractionated radiation in advanced squamous cell carcinoma of the buccal mucosa: a retrospective cohort study. Biomed Res Int (2015) 0.75
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys (2000) 7.50
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol (2003) 6.82
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med (1998) 5.20
Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst (1999) 5.15
The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol (1988) 3.43
Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol (1992) 3.30
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2001) 3.17
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet (2003) 2.54
Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol (2000) 2.45
Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst (1996) 2.41
A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol (1997) 2.35
Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. Radiother Oncol (2003) 2.32
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol (1997) 2.23
Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol (1998) 1.74
Radiation dose-response of human tumors. Int J Radiat Oncol Biol Phys (1995) 1.73
Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys (1997) 1.58
Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys (1990) 1.55
A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys (1993) 1.50
Local control, TCD50 and dose-time prescription habits in radiotherapy of head and neck tumours. Radiother Oncol (1994) 1.48
Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys (2003) 1.31
Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol (1997) 1.23
A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys (1985) 1.18
Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity. Radiother Oncol (2000) 1.07
Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial. Int J Radiat Oncol Biol Phys (2003) 1.06
Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol (1976) 0.97
Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. J Clin Oncol (1997) 0.94
Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys (1991) 0.93
Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol (1987) 0.89
Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol (1994) 0.88
Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. Radiother Oncol (1998) 0.85
Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol (2000) 0.84
A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother Oncol (2001) 0.84
Hyperfractionation: where do we stand? Radiother Oncol (1997) 0.82
The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects. Radiother Oncol (1995) 0.81
Simultaneous chemoradiation in the treatment of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg (1992) 0.80
Management of stages III and IV head and neck cancer. Int J Radiat Oncol Biol Phys (1990) 0.79
A randomized trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (1992) 0.78
Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report. Int J Radiat Oncol Biol Phys (1998) 0.78
Outcome of hyperfractionated radiation therapy in randomized clinical trials. Int J Radiat Oncol Biol Phys (1998) 0.78
A malaria model tested in the African savannah. Bull World Health Organ (1974) 5.74
Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet (2001) 3.36
A structured epidemic model incorporating geographic mobility among regions. Math Biosci (1995) 2.50
Contact tracing in stochastic and deterministic epidemic models. Math Biosci (2000) 2.44
Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol (2004) 2.34
Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys (2000) 2.33
Progress in chimerism analysis in childhood malignancies--the dilemma of biostatistical considerations and ethical implications. Leukemia (2001) 2.02
The effect of household distribution on transmission and control of highly infectious diseases. Math Biosci (1995) 1.94
Infection with human T-cell leukemia virus type I in patients with leukemia. N Engl J Med (1988) 1.78
Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood (2001) 1.76
Genesis, sequestration and survival of Plasmodium falciparum gametocytes: parameter estimates from fitting a model to malariatherapy data. Trans R Soc Trop Med Hyg (2001) 1.75
Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A (1998) 1.72
Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients. Crit Care Med (2001) 1.70
Plasmodium falciparum parasitaemia described by a new mathematical model. Parasitology (2001) 1.55
[Radiation tolerance of the human spinal cord]. Strahlenther Onkol (1994) 1.50
Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol (2001) 1.47
Hypericin uptake: a prognostic marker for survival in high-grade glioma. J Clin Neurosci (2008) 1.40
Age and seasonal variation in the transition rates and detectability of Plasmodium falciparum malaria. Parasitology (2006) 1.40
Epidemiologic interference of virus populations. J Math Biol (1979) 1.37
Further epidemiological evaluation of a malaria model. Bull World Health Organ (1978) 1.37
Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology (1997) 1.35
Antibody against hepatitis A in seven European countries. II. Statistical analysis of cross-sectional surveys. Am J Epidemiol (1979) 1.35
Malariometric update for the rainforest and savanna of Ashanti region, Ghana. Ann Trop Med Parasitol (2000) 1.33
Heterogeneities in schistosome transmission dynamics and control. Parasitology (1998) 1.33
The effect of pair formation and variable infectivity on the spread of an infection without recovery. Math Biosci (1998) 1.32
A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections. Infect Immun (1993) 1.30
Some bounds on estimates for reproductive ratios derived from the age-specific force of infection. Math Biosci (1994) 1.29
The protective effect of condoms and nonoxynol-9 against HIV infection. Am J Public Health (1998) 1.28
Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene (2000) 1.27
Diagnosis and monitoring of murine histoplasmosis by a nested PCR assay. J Clin Microbiol (2001) 1.27
Distribution of survival times of deliberate Plasmodium falciparum infections in tertiary syphilis patients. Trans R Soc Trop Med Hyg (2006) 1.26
Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant (2000) 1.26
Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children. Pediatr Infect Dis J (2000) 1.25
Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol (2011) 1.24
Lipopolysaccharide activates caspase-1 (interleukin-1-converting enzyme) in cultured monocytic and endothelial cells. Blood (1998) 1.22
Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma. J Glaucoma (2001) 1.21
Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours. Onkologie (2004) 1.21
Multiplication of different Legionella species in Mono Mac 6 cells and in Acanthamoeba castellanii. Appl Environ Microbiol (1997) 1.21
Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol (1999) 1.20
Commissioning of a micro multi-leaf collimator and planning system for stereotactic radiosurgery. Radiother Oncol (1999) 1.18
Association of a new mannose-binding lectin variant with severe malaria in Gabonese children. Genes Immun (2006) 1.16
Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids. Proc Natl Acad Sci U S A (1999) 1.15
Immune depression syndrome following human spinal cord injury (SCI): a pilot study. Neuroscience (2008) 1.14
Tumor radiosensitivity prediction by the cytokinesis-block micronucleus assay. Radiat Res (1991) 1.14
Review of intra-host models of malaria. Parassitologia (1999) 1.14
Modelling patterns of parasite aggregation in natural populations: trichostrongylid nematode-ruminant interactions as a case study. Parasitology (1995) 1.14
Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin Infect Dis (2001) 1.13
[Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study]. Strahlenther Onkol (1999) 1.13
Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene (2006) 1.13
New standardised texts for assessing reading performance in four European languages. Br J Ophthalmol (2006) 1.11
Prediction of subclinical tumor infiltration in basal cell carcinoma. J Dermatol Surg Oncol (1991) 1.11
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost (2007) 1.11
The impact of propoxur on Anopheles gambiae s.1. and some other anopheline populations, and its relationship with some pre-spraying variables. Bull World Health Organ (1976) 1.09
Image guided respiratory gated hypofractionated Stereotactic Body Radiation Therapy (H-SBRT) for liver and lung tumors: Initial experience. Acta Oncol (2006) 1.08
The vascular system of xenotransplanted tumors--scanning electron and light microscopic studies. Scanning Microsc (1989) 1.07
Modelling the transition of asexual blood stages of Plasmodium falciparum to gametocytes. J Theor Biol (2000) 1.06
Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging (2005) 1.06
Changes in mitotic rate and cell cycle fractions caused by delayed fixation. Hum Pathol (1990) 1.06
Methods for analysis of censored tumor growth delay data. Radiat Res (1990) 1.05
The basic reproduction ratio for sexually transmitted diseases: I. Theoretical considerations. Math Biosci (1991) 1.05
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer (2006) 1.04
Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer (2004) 1.04
On the interpretation of age-intensity profiles and dispersion patterns in parasitological surveys. Parasitology (2003) 1.04
Impact of the filling status of the bladder and rectum on their integral dose distribution and the movement of the uterus in the treatment planning of gynaecological cancer. Radiother Oncol (1999) 1.03
Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis. Strahlenther Onkol (1998) 1.01
Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? Am J Epidemiol (1996) 1.01
Density-dependent parasite establishment suggests infection-associated immunosuppression as an important mechanism for parasite density regulation in onchocerciasis. Trans R Soc Trop Med Hyg (2003) 1.00
Plasmodium falciparum: in vitro growth inhibition by febrile temperatures. Parasitol Res (2001) 0.99
Wild-type, mitochondrial and ER-restricted Bcl-2 inhibit DNA damage-induced apoptosis but do not affect death receptor-induced apoptosis. J Cell Sci (2001) 0.99
Subcellular distribution of glucose transporter (GLUT-1) during development of the blood-brain barrier in rats. Cell Tissue Res (1996) 0.99
Proportionate mixing models for age-dependent infection transmission. J Math Biol (1985) 0.97
The effect of immigration on genetic control. Theor Popul Biol (1976) 0.96
Comparison of MR-thermography and planning calculations in phantoms. Med Phys (2006) 0.95
Treatment of early stage testicular seminoma. J Cancer Res Clin Oncol (2001) 0.95
Factors influencing the absorbed dose in intraoral radiography. Dentomaxillofac Radiol (2007) 0.95
Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol (1998) 0.94
[Epidemiology of rabies in wildlife. Studies in the southern part of the Federal Republic of Germany]. Zentralbl Veterinarmed B (1974) 0.94
Characteristics of the spread of a wildlife rabies epidemic in Europe. Bull World Health Organ (1976) 0.93
Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors. Eur J Nucl Med Mol Imaging (2006) 0.93
Radiotherapy with and without temozolomide in elderly patients with glioblastoma. Strahlenther Onkol (2012) 0.92
The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). Ann Oncol (2011) 0.92
Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode. Cell Death Dis (2013) 0.92
Milk fat globule-EGF factor 8 mediates the enhancement of apoptotic cell clearance by glucocorticoids. Cell Death Differ (2013) 0.92
Radioresponsiveness of human glioma, sarcoma, and breast cancer spheroids depends on tumor differentiation. Int J Radiat Oncol Biol Phys (1993) 0.92
Analysis of a model for the pathogenesis of AIDS. Math Biosci (1997) 0.92
Stochastic models for aggregation processes. Math Biosci (2000) 0.91
Hippocampus sparing in whole-brain radiotherapy. A review. Strahlenther Onkol (2014) 0.91
Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol (1995) 0.91
PCV chemotherapy for recurrent glioblastoma. Neurology (2006) 0.91
Inhibition of Jurkat-T-lymphocyte Na+/H+-exchanger by CD95(Fas/Apo-1)-receptor stimulation. Pflugers Arch (2000) 0.91
Malaria therapy reinoculation data suggest individual variation of an innate immune response and independent acquisition of antiparasitic and antitoxic immunities. Trans R Soc Trop Med Hyg (2002) 0.90
Evaluation of a commercial IgG/IgM Western blot assay for early postnatal diagnosis of congenital toxoplasmosis. Eur J Clin Microbiol Infect Dis (2003) 0.90
Sonographic assessment of the fetal palpebral fissure slant--an additional tool in the prenatal diagnosis of syndromes. Prenat Diagn (1997) 0.89
The relationships between the burden of adult parasites, host age and the microfilarial density in human onchocerciasis. Int J Parasitol (2004) 0.89
Influence of Acanthamoeba castellanii on intracellular growth of different Legionella species in human monocytes. Appl Environ Microbiol (2000) 0.88